SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology Treatment…
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.